Azitra Inc (NYSE MKT:AZTR) — Market Cap & Net Worth
Market Cap & Net Worth: Azitra Inc (AZTR)
Azitra Inc (NYSE MKT:AZTR) has a market capitalization of $3.19 Million ($3.19 Million) as of May 22, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #29295 globally and #5833 in its home market, demonstrating a -10.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Azitra Inc's stock price $0.20 by its total outstanding shares 16192438 (16.19 Million). Analyse AZTR operating cash flow to see how efficiently the company converts income to cash.
Azitra Inc Market Cap History: 2023 to 2026
Azitra Inc's market capitalization history from 2023 to 2026. Data shows growth from $446.91 Million to $3.19 Million (236.87% CAGR).
Azitra Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Azitra Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.92x
Azitra Inc's market cap is 0.92 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $446.91 Million | $686.00K | -$11.28 Million | 651.47x | N/A |
| 2024 | $6.89 Million | $7.50 Million | -$8.97 Million | 0.92x | N/A |
Competitor Companies of AZTR by Market Capitalization
Companies near Azitra Inc in the global market cap rankings as of May 22, 2026.
Key companies related to Azitra Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #224 globally with a market cap of $109.25 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #410 globally with a market cap of $66.94 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #573 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #593 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #224 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.25 Billion | $430.44 |
| #410 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $66.94 Billion | $649.76 |
| #573 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #593 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
Azitra Inc Historical Marketcap From 2023 to 2026
Between 2023 and today, Azitra Inc's market cap moved from $446.91 Million to $ 3.19 Million, with a yearly change of 236.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.19 Million | -25.66% |
| 2025 | $4.29 Million | -37.72% |
| 2024 | $6.89 Million | -98.46% |
| 2023 | $446.91 Million | -- |
End of Day Market Cap According to Different Sources
On May 21st, 2026 the market cap of Azitra Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.19 Million USD |
| MoneyControl | $3.19 Million USD |
| MarketWatch | $3.19 Million USD |
| marketcap.company | $3.19 Million USD |
| Reuters | $3.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Azitra Inc
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer pat… Read more